Cryo-Save Group N.V.
amsterdam : CRYO

May 25, 2011 01:09 ET

Cryo-Save Group NV on track to launch Cryo-Lip® in the US

ZUTPHEN, NETHERLANDS--(Marketwire - May 25, 2011) -


Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international family stem cell bank, announces that it has incorporated a wholly owned subsidiary in Delaware, USA. The subsidiary is called Cryo-Save USA, Inc. and will commercialize and further develop the Cryo-Lip® service in North America. Cryo-Lip® allows adults to store stem cells from fat tissue which is extracted whilst undergoing other surgical procedures.

Preparations towards a full launch of this service in the US are on schedule and Cryo-Save expects to store its first commercial US samples in Q3 2011.

Cryo-Save USA has already entered into an agreement with General BioTechnology LLC ("GBT") in Indianapolis. GBT is a FDA and AABB (American Association of Blood Banks) accredited stem cell bank and will be the strategic partner responsible for processing and the long-term cryogenic storage of stem cells from fat tissue.

In order to maintain Cryo-Save's reputation for adhering to the highest scientific and quality standards, a validation study for Cryo-Lip® has been initiated in the US. Adipose (fat) tissue samples are collected from clinics and the quality and quantity of adipose-derived stem cells are analyzed following processing and cryopreservation.

Arnoud van Tulder, Chief Executive of Cryo-Save commented:

"We are excited about the progress made so far in the US and the opportunity for us to gain a leading position in adult stem cell storage in the US as well as in Europe.

"Our partnership with GBT will ensure that our work in the US meets Cryo- Save's renowned high standards and our focus now will be on creating a strong commercial network".

Free footage is available on www.videobankonline.com

About Cryo-Save (www.cryo-save.com/group)

Cryo-Save, the leading international family stem cell bank, already stores 175,000 samples from cord blood and umbilical cord tissue for newborns and adipose tissue for adults. These stem cells can mean the difference between life and death in the case of future threats to the health of the donors. There are already several diseases that can be cured by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in 40 countries on three continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India and France (validation in progress).


Click here for press release in PDF: http://hugin.info/143308/R/1518174/454707.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Cryo-Save Group N.V. via Thomson Reuters ONE

[HUG#1518174]

Contact Information

  • Enquiries:

    Cryo-Save Group
    + 31 (0) 575 548 998
    Arnoud van Tulder
    Chief Executive Officer

    SPJ Financiele Communicatie (The Netherlands)
    +31 (0)20 647 8181
    Kees Jongsma
    Leon Melens

    Daniel Stewart & Company plc (UK)
    + 44 (0) 20 7776 6550
    Sean Lunn

    College Hill (UK)
    + 44 (0) 20 7457 2020
    Rozi Morris
    Adrian Duffield